Abstract:Dermatomyositis (DM) represents a multifaceted chronic inflammatory myopathy, primarily manifesting as progressive deterioration of muscular and cutaneous tissues. Despite an incomplete comprehension of DM's etiology and pathogenesis, current evidence implicates the involvement of T lymphocyte infiltration, extensive cytokine release, myositis-specific antibodies, and myositis-associated antibodies in disease development. Serum soluble interleukin-2 receptor (sIL-2R) frequently serves as a marker for T cell activation; however, its role remains elusive. Consequently, this investigation sought to elucidate the association between sIL-2R levels, peripheral blood lymphocyte subset counts, and related cytokines in DM patients, with the aim of uncovering the intricate mechanisms underlying DM and establishing a theoretical foundation for the implementation of precise, targeted, individualized immunomodulatory therapy. In this study, a cohort of 60 dermatomyositis (DM) patients, comprising 32 with inactive DM and 28 with active DM, was enrolled and stratified into inactive and active groups based on the Myositis Disease Activity Visual Analogue Scale (MYOACT). Flow cytometry was employed to quantify the absolute counts of peripheral lymphocyte subsets and CD4+T cell subsets in each group, while a flow cytometry bead array was utilized to measure serum cytokine levels. In a comparative analysis between healthy individuals and patients diagnosed with DM, we observed a marked elevation in serum sIL-2R concentrations ( P < 0.001) and T-helper 17 cell/regulatory T cell (Th17/Treg) ratios ( P < 0.01) within the latter group. A positive correlation was identified between serum sIL-2R levels and various parameters, including ESR, CRP, VAS, AST, CKMB, LDH, HBDH, PT, APTT, DDi, IL-6, IL-10, and IFN-γlevels ( P < 0.05). In contrast, serum sIL-2R levels demonstrated a negative correlation with LY, HGB, ALB, Th17 cell populations, and Th17/Treg cell ratios ( P < 0.05). Employing multivariate logistic regression, we identified serum sIL-2R concentrations as an independent risk factor for both disease activity and hepatic involvement in DM patients. Moreover, receiver operating characteristic (ROC) curve analyses revealed that serum sIL-2R levels significantly contributed to the differentiation of disease activity and the detection of liver involvement in DM patients, with areas under the ROC curve (AUC) of 0.757 (95% CI 0.630–0.884, P = 0.001) and 0.826 (95% CI 0.717–0.935, P < 0.001), respectively. This study highlights the potential utility of serum sIL-2R levels as a valuable biomarker for assessing disease activity and liver involvement in dermatomyositis. Elevated serum concentrations of sIL-2R were observed in patients with DM, exhibiting significant associations with Th17 cell populations and Th17/ Treg ratios. These findings indicate that sIL-2R may be implicated in the immunopathogenesis of DM, thereby warranting further investigation to elucidate its role in the disease process.

Measurement of Cytokines and Chemokines and Association with Clinical Severity of Dermatomyositis and Clinically Amyopathic Dermatomyositis.

Polymyositis and Dermatomyositis Biomarkers

Detection of serum cytokines in patients with dermatomyositis and their clinical significance

Serum Levels of Interleukins and S100A8/A9 Correlate with Clinical Severity in Patients with Dermatomyositis-Associated Interstitial Lung Disease

Identification of Distinct Cytokine/chemokine Profiles in Dermatomyositis with Anti-Transcriptional Intermediary Factor 1-Γ Antibody

Clinical Nomogram Assisting in Discrimination of Juvenile Dermatomyositis-Associated Interstitial Lung Disease.

Serum IL8 and mRNA level of CD11b in circulating neutrophils are increased in clinically amyopathic dermatomyositis with active interstitial lung disease

Comparison of Cytokine/chemokine Profiles Between Dermatomyositis and Anti-Synthetase Syndrome

Correlation of cytokines levels with interstitial lung disease in patients with inflammatory myopathy

Detection of Anti-Cadm-140 Antibody in Patients with Dermatomyositis or Clinically Amyopathic Dermatomyositis and Its Clinical Significance

Serum S100A12 Levels Are Correlated with Clinical Severity in Patients with Dermatomyositis-Associated Interstitial Lung Disease.

Comparison of Clinical and Immunological Features Between Clinically Amyopathic Dermatomyositis and Typical Dermatomyositis

Increased serum soluble interleukin-2 receptor levels in dermatomyositis are associated with Th17/Treg immune imbalance

Serum interleukin-34 levels in dermatomyositis: a potential biomarker for anti-MDA5-antibody-associated interstitial lung disease

Analysis for the Organ Involvement and Immnunological Markers of the Patients with Dermatomyositis

[A Clinical Analysis of Dermatomyositis with Interstitial Lung Disease in 20 Patients].

Clinical Manifestations of Dermatomyositis and Clinically Amyopathic Dermatomyositis Patients with Positive Expression of Anti–melanoma Differentiation–associated Gene 5 Antibody

Risk Factors of Interstitial Lung Diseases in Clinically Amyopathic Dermatomyositis

IFN-beta and EIF2AK2 Are Potential Biomarkers for Interstitial Lung Disease in Anti-Mda5 Positive Dermatomyositis.

Mir-125B, Mir-200C Are Correlated with the Severity of Interstitial Lung Disease in Dermatomyositis/Polymyositis

Correlation of increased serum leucine-rich α2-glycoprotein levels with disease prognosis, progression, and activity of interstitial pneumonia in patients with dermatomyositis: A retrospective study